Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan

OBJECTIVES: To estimate appropriate dose-volume parameters for avoidance of pneumonitis in use of chemoradiotherapy and durvalumab for treatment of lung cancer. MATERIALS AND METHODS: Patients with non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab at 9 cente...

Descripción completa

Detalles Bibliográficos
Autores principales: Oshiro, Yoshiko, Mizumoto, Masashi, Sekino, Yuta, Maruo, Kazushi, Ishida, Toshiki, Sumiya, Taisuke, Nakamura, Masatoshi, Ohkawa, Ayako, Takizawa, Daichi, Okumura, Toshiyuki, Tamaki, Yoshio, Sakurai, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190008/
https://www.ncbi.nlm.nih.gov/pubmed/34151033
http://dx.doi.org/10.1016/j.ctro.2021.05.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190008/
https://www.ncbi.nlm.nih.gov/pubmed/34151033
http://dx.doi.org/10.1016/j.ctro.2021.05.009

Ejemplares similares